Cryopreservation of human embryos and oocytes

Mandelbaum, J.; Junca, A. M.; Plachot, M.; Alnot, M. O.; Salat-Baroux, J.; Alvarez, S.; Tibi, C.; Cohen, Jacques; Debache, C.; Tesquier, L

doi:10.1093/oxfordjournals.humrep.a136642

Cited by 104 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some reports have highlighted a protective effect of cumulus cells for their ability to make CPAs penetration more gradual during cooling and protect against rapid osmotic changes during CPAs removal in thawing procedure [53], inducing an increment in survival and fertilization rates [54]. On the other hand, other studies have suggested that cumulus cells do not have protective effects and that they interfere with the CPAs passage through ooplasm [55]. Moreover, intercellular contacts, which establish functional connections between cumulus and oocyte and facilitate communication among cumulus cells themselves, may act as potential nucleation sites that could initiate ice crystals formation between neighbouring cells [56].…”

Section: Oocyte-cumulus Cell Contact and Interactionmentioning

confidence: 99%

The current challenges to efficient immature oocyte cryopreservation

Brambillasca

Guglielmo

Coticchio

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Oocyte cryopreservation represents an important tool for assisted reproductive technology. It offers the opportunity to preserve fertility in women at risk of loss of the ovarian function for various pathologies. It also represents a treatment alternative for couples that cannot benefit from embryo cryopreservation because of moral, religious, or legal constrains. On the other hand, in vitro oocyte maturation has a range of applications. It can be applied in patients with a contraindication to ovarian stimulation to prevent ovarian hyperstimulation syndrome or to eliminate the risk of stimulation of hormone-sensitive tumours in cancer patients. However, while mature oocyte cryopreservation has found widespread application and oocyte in vitro maturation has a place for the treatment of specific clinical conditions, data on the efficiency of freezing of immature or in vitro matured oocytes are poorer. In this review we will focus on the combination of oocyte in vitro maturation with oocyte cryopreservation with particular emphasis on the biological implications of the cryopreservation of immature or in vitro matured oocytes. The two cryopreservation approaches, slow freezing and vitrification, will be discussed in relation to possible cryodamage occurring to subcellular structures of the oocyte and the functional interaction between oocyte and cumulus cells.

show abstract

Section: Oocyte-cumulus Cell Contact and Interactionmentioning

confidence: 99%

The current challenges to efficient immature oocyte cryopreservation

Brambillasca

Guglielmo

Coticchio

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Cryopreservation of immature GV-stage oocytes has been investigated as an alternative to freezing mature MII stage oocytes (43)(44)(45)(46)(47). In GV-stage oocytes, the chromatin is diffuse and surrounded by a nuclear membrane.…”

Section: Figurementioning

confidence: 99%

Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation

Huang

Tulandi

Holzer

et al. 2008

Fertility and Sterility

185

View full text Add to dashboard Cite

“…Unless noted otherwise, all studies discussed herein are in human. Table 2 summarizes the ranges of values obtained from a total of 23 studies that cryopreserved human oocytes at the GV stage, 14 and 12 of which used slow-freezing or vitrification protocols, respectively (Mandelbaum et al, 1988;Toth et al, 1994a;Toth et al, 1994b;Baka et al, 1995;Son et al, 1996;Park et al, 1997;Chung et al, 2000;Goud et al, 2000;Wu et al, 2001;Boiso et al, 2002;Chen et al, 2004;Fuchinoue et al, 2004;Isachenko et al, 2006;Cao et al, 2009;Fasano et al, 2010;Al-Khtib et al, 2011;Combelles et al, 2011;Criado et al, 2011;Liu et al, 2011;Versieren et al, 2011;Zhang et al, 2011;Fasano et al, 2012;Wang et al, 2012). Seventy percent (16/23) of studies evaluated the in vitro developmental competence of cryopreserved GV oocytes based on fertilization, cleavage, and in some instances even blastocyst formation.…”

Section: Advantages and Drawbacks Of Cryopreserving Immature Oocytes mentioning

confidence: 99%

The use of immature oocytes in the fertility preservation of cancer patients: current promises and challenges

Combelles¹,

Chateau²

2012

Int. J. Dev. Biol.

View full text Add to dashboard Cite

Improved oncological treatments permit increased survival rates, although cancer patients remain at risk of losing ovarian function. An attractive option for fertility preservation includes the use of immature oocytes, a strategy which can occur on a rapid timeline and without hormonal stimulation. As a result, cancer therapy can proceed promptly even in patients with hormone-sensitive tumors. Following retrieval, immature oocytes can be cryopreserved at either the immature germinal vesicle or the mature metaphase-II stage, i.e. either before or after in vitro maturation (IVM). We present a critical review of previous human studies on the cryopreservation of immature oocytes. Evaluations include in vitro developmental competence upon thawing/warming, or organization of the spindle and chromosomes. Reported successes vary, perhaps in relation to the source of the oocytes and protocols for cryopreservation and IVM. Weaknesses exist with the experimental designs implemented to date, so caution must be exercised before considering the use of immature oocytes to be a safe and reliable practice in the fertility preservation of cancer patients. To date, results indicate that with current protocols, it may be best to cryopreserve immature oocytes after IVM at the metaphase-II stage. Nonetheless, efficacy remains very low. Future efforts should tailor and optimize not only cryopreservation, but also IVM protocols for use in either germinal vesicle or metaphase-II oocytes, together with a comprehensive assessment of oocyte function and developmental competence to term. Despite current challenges, the burgeoning field of immature oocyte cryopreservation constitutes a promising option for cancer patients with impaired ovarian function. KEY WORDS: immature oocyte, fertility preservation, cryopreservation, cancer, in vitro maturation Why target immature oocytes in cancer patients?In the last few decades, the incidence of cancer and the likelihood of survival have risen across the globe. A little over 1 in 3 women in North America are diagnosed with cancer every year. This constitutes an overwhelming number of young women of reproductive age undergoing chemotherapy, radiotherapy, and other oncologic treatments; an estimated 9% of cancer survivors are 20-39 years old in the United States. Invasive cancers are treated aggressively through chemotherapy, radiotherapy and surgeries to remove cancerous cells and masses. Unfortunately such treatments create irreversible damage to the gonads and possible sterility (reviewed by Anchan and Ginsburg, 2010). Depending on the type and dose, oncological therapies may result in damage and/or loss of not only germ cells but also the supporting somatic compartments of the ovarian follicle. Due to the women's finite number of oocytes and the irreplaceable nature of the pool Int. J. Dev. Biol. 56: 919-929 (2012)

show abstract

Cryopreservation of human embryos and oocytes

Cited by 104 publications

References 0 publications

The current challenges to efficient immature oocyte cryopreservation

The current challenges to efficient immature oocyte cryopreservation

Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation

The use of immature oocytes in the fertility preservation of cancer patients: current promises and challenges

Contact Info

Product

Resources

About